MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damage

Amplification of the MYC proto-oncogene is frequently observed in various cancer types, including triple-negative breast cancer (TNBC). Emerging evidence suggests that suppression of local antitumor immune responses by MYC, at least in part, explains the tumor-promoting effects of MYC. Specifically,...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry Vol. 301; no. 6; p. 108560
Main Authors: Linstra, Renske, Stappenbelt, Chantal, Bakker, Femke J., Everts, Marieke, Bhattacharya, Arkajyoti, Yu, Shibo, van Bergen, Stella D., van der Vegt, Bert, Wisman, G. Bea A., Fehrmann, Rudolf S.N., de Bruyn, Marco, van Vugt, Marcel A.T.M.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 01.06.2025
American Society for Biochemistry and Molecular Biology
Subjects:
breast cancer
Cell Line, Tumor
DNA Damage
Down-Regulation
Female
Gene Expression Regulation, Neoplastic
Humans
Inflammation - genetics
Inflammation - metabolism
innate immunity
interferon
Membrane Proteins - genetics
Membrane Proteins - metabolism
Myc (c-MYC)
Proto-Oncogene Mas
Proto-Oncogene Proteins c-myc - genetics
Proto-Oncogene Proteins c-myc - metabolism
Signal Transduction
STAT1 Transcription Factor - genetics
STAT1 Transcription Factor - metabolism
STAT3 Transcription Factor - genetics
STAT3 Transcription Factor - metabolism
transcription regulation
Triple Negative Breast Neoplasms - genetics
Triple Negative Breast Neoplasms - immunology
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - pathology
tumor immunology
transcription regulation
tumor immunology
HRP
breast cancer
interferon
ChIP
Dox
PBMC
IFN
innate immunity
FCS
cGAS
MCP-counter
STING
cDNA
TNBC
METABRIC
Myc (c-MYC)
ISRE
ISSN:0021-9258, 1083-351X, 1083-351X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amplification of the MYC proto-oncogene is frequently observed in various cancer types, including triple-negative breast cancer (TNBC). Emerging evidence suggests that suppression of local antitumor immune responses by MYC, at least in part, explains the tumor-promoting effects of MYC. Specifically, MYC upregulation was demonstrated to suppress the tumor-cell intrinsic activation of a type I interferon response and thereby hamper innate inflammatory signaling, which may contribute to the disappointing response to immunotherapy in patients with TNBC. In this study, we show that MYC interferes with protein expression and functionality of the STING pathway. MYC-mediated STING downregulation in BT-549 and MDA-MB-231 TNBC cell lines requires the DNA-binding ability of MYC and is independent of binding of MYC to its co-repressor MIZ1. Both STAT1 and STAT3 promote the steady-state expression levels of STING, and STAT3 cooperates with MYC in regulating STING. Conversely, MYC-mediated downregulation of STING affects protein levels of STAT1 and downstream chemokine production. Furthermore, we show that MYC overexpression hampers immune cell activation triggered by DNA damage through etoposide or irradiation treatment and specifically impedes the activation of natural killer cells. Collectively, these results show that MYC controls STING levels and thereby regulates tumor cell-intrinsic inflammatory signaling. These results contribute to our understanding of how MYC suppresses inflammatory signaling in TNBC and may explain why a large fraction of patients with TNBC do not benefit from immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0021-9258
1083-351X
1083-351X
DOI:10.1016/j.jbc.2025.108560